Abstract. Propofol is widely used for the induction and maintenance of pediatric anesthesia. Previous studies have indicated that propofol can induce apoptosis, and damage cognitive and memory functions. Dexmedetomidine is a potent α-2 adrenoceptor agonist with high selectivity. Previous observations have shown that dexmedetomidine exhibits anti-apoptotic qualities. The present study evaluated the neuroprotective effects of dexmedetomidine pretreatment against propofol-induced neurotoxicity in immature hippocampal neurons. The viability and apoptotic rate of the neurons were detected using a Cell Counting Kit-8 assay and flow cytometry. The mRNA and protein expression levels of brain-derived neurotrophic factor (BDNF), B-cell lymphoma-2 (Bcl-2) and phosphorylated-cyclic-AMP response element binding protein (p-CREB) were detected using semiquantitative reverse transcription-polymerase chain reaction and western blot analyses, respectively. These results showed that propofol exposure (100 µM; 3 h) reduced neuronal viability, induced cell apoptosis and decreased the expression levels of BDNF, Bcl-2 and p-CREB. Dexmedetomidine treatment (0.001-100 µM) of the neurons prior to propofol exposure attenuated the propofol-induced neuronal apoptosis and increased expression levels of BDNF, Bcl-2 and p-CREB compared with the propofol only group. In addition, dexmedetomidine at the highest concentration provided superior neuroprotection of neurons. These in vitro data indicated that dexmedetomidine exerted direct neuroprotective effects to prevent cultured hippocampal neuronal injury caused by propofol, accompanied by an increase in the levels of p-CREB, Bcl-2 and BDNF.
Introduction
There has been an increase in the number of studies examining the possible detrimental effects of anesthesia in the developing brain. Propofol (2,6-diisopropylphenol) is a sedative-hypnotic agent widely used for the induction and maintenance of anesthesia in surgery, and sedation in intensive care units. It has been reported that propofol exposure can induce cell death in neural precursor or stem cells (1) , immature hippocampal neurons (2) and cortical cells (3) in vitro. Several in vivo studies have also demonstrated that propofol can cause neuronal cell apoptosis in the developing brain of rodents (4, 5) and non-human primates (NHPs) (6) . Therefore, it is important to develop promising strategies for protection of the developing brain from the potentially deleterious effects of propofol.
Dexmedetomidine is an α-2 adrenoceptor agonist with high selectivity, and with sympatholytic, sedative and analgesic properties. It is considered to offer potential benefits towards neuroprotection (7) . In a murine model of perinatal excitotoxic brain damage, dexmedetomidine has been found to provide potent neuroprotection (8) . Previous in vitro and in vivo observations have demonstrated that dexmedetomidine protects against neuroapoptosis induced by isoflurane in the hippocampus of neonatal rats (9, 10) . Isoflurane is a type of volatile anesthetic and it is reported to cause a similar pattern of neuronal apoptosis as propofol in the neonatal brain (6) . Anesthesia-induced apoptotic damage in the developing brain is regulated, at least in part, by the brain-derived neurotrophic factor (BDNF)-modulated apoptotic cascade (11) . In addition, it has been reported that the neuroprotective effects of dexmedetomidine are mediated by upregulating the levels of BDNF, phosphorylated-cyclic-AMP response element binding protein (p-CREB) (12, 13) and the antiapoptotic factor, B-cell lymphoma 2 (Bcl-2) (14) .
The present study used neuronal cultures from the rat hippocampus to investigate whether dexmedetomidine pretreatment is able to effectively attenuate propofol-induced Dexmedetomidine pretreatment attenuates propofol-induced neurotoxicity in neuronal cultures from the rat hippocampus YI neurotoxicity in vitro. The study also aimed to examine alterations in the expression levels of p-CREB, Bcl-2 and BDNF following exposure to propofol and dexmedetomidine.
Materials and methods
Hippocampal neuronal culture and drug treatment. The experimental procedure was approved by the Animal Use and Care Committee of Guangxi Medical University (Guangxi, China) and performed in strict accordance with the guidelines of the National Institutes of Health Guide for the Use of Laboratory Animals. Primary hippocampal cultures were prepared, as described previously (15) . In brief, 40 female Sprague-Dawley rats (age, 4 months; weight, 400-450 g) in advanced pregnancy (Guangxi Medical University Laboratory Animal Co.; permission no. SCXK 2009-0002) were housed under standard conditions with a 12-h light/dark cycle at 23±2°C, 50±5% relative humidity and free access to food and water. The rats were then anesthetized using 10% (w/v) chloral hydrate (3.5 ml/kg; Sigma-Aldrich, Merck Millipore, Darmstadt, Germany) and embryonic day 16-18 fetuses were removed. Next, the pregnant rats were sacrificed by cervical dislocation. The fetuses were sacrificed by rapid decapitation, followed by immediate removal of the brain and its surrounding membranes. The hippocampus was then rapidly dissected from the cortex. The meningeal tissues were removed and the hippocampus was dissociated mechanically into 1 mm 3 pieces. Equal volume of 0.25% trypsin solution (Sigma-Aldrich, Merck Millipore) was added to the dissected tissue and incubated at 37°C for 15 min, mixing every 5 min. Following the removal of the trypsin solution, 1 ml precooled fetal calf serum (FCS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was added into the tissue, mixed gently, and incubated in a 37°C water bath for 5 min to stop the digestion. The tissues were centrifuged for 5 min at 106 x g and the supernatant was discarded. Cells were washed three times and resuspended in plating medium [Neurobasal medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FCS, 0.2 mM glutamine, 100 U/ml penicillin and 100 U/ml streptomycin] and were transferred as a 0.5 ml aliquot to a tube that contained 0.5 ml of 4% Typan blue. The number of Trypan blue-excluding cells were counted by inverted microscope (Olympus Corporation, Tokyo, Japan). The number of Trypan blue-excluding cells were counted, and the cells were plated onto six-well culture plates (Corning, Inc., Acton, MA, USA) previously coated with poly-L-lysine (0.1 mg/ml, Gibco; Thermo Fisher Scientific, Inc.) at a density of 5x10 4 cells/ml. The cultures were maintained at 37˚C with 5% CO 2 , supplemented with Neurobal medium with 2% B-27 (Gibco; Thermo Fisher Scientific, Inc.), 2 mmol/ml glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml). Half the cell culture media was replaced every 3 days. Immunocytochemical staining was performed on neurons maintained for 8 days in vitro (DIV 8) using mouse monoclonal antibody against NeuN (cat. no. ABN78; Chemicon, Temecula, CA, USA). The cells adhered to and grew on the coverslips. Following fixing with 4% paraformaldehyde, coverslips bearing the neuronal cultures were pre-incubated in 5% goat serum in phosphate-buffered saline (PBS) supplemented with 0.2% Triton-X 100 for 1 h at room temperature, followed by incubation with the primary antibody (1:500 dilution) overnight at 4˚C. Binding of the NeuN antibody was detected with a goat anti-mouse IgG biotinylated secondary antibody (1:5,000; cat. no. ab32096; Abcam, Cambridge, MA, USA). 3,3'-Diaminobenzidine tetrahydrochloride was used as the substrate. Staining for NeuN was then visualized using an AxioM1 light microscope (BX53; Olympus Corporation).
The DIV 8 primary hippocampal cultures were used for the drug exposure experiments in the present study. The cells were seeded at a density of 5.0x10 4 cells/well and were assigned to a control group, propofol group and dexmedetomidine + propofol groups. The cells in the control group were incubated without drugs in an intralipid vehicle (Baxter, Guangzhou, China) at 37˚C for 3 h, whereas the cells in the propofol group were incubated with 100 µM propofol for 3 h at 37˚C in the absence of dexmedetomidine pretreatment. The cells in the dexmedetomidine + propofol groups were incubated with 0.001, 0.01, 0.1, 1, 10 or 100 µM dexmedetomidine, respectively, at 37˚C for 30 min, following which 100 µM propofol was added to the culture medium at 37˚C for 3 h. The viability and apoptotic rate of the neurons were then detected using a Cell Counting Kit-8 (CCK-8) assay and flow cytometry. The expression levels of BDNF, Bcl-2 and p-CREB were detected using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and western blot analyses.
Cell viability assay. Cell viability was assessed using a CCK-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). The cells were incubated with 100 µM propofol for 3 h in the absence or presence of dexmedetomidine pretreatment, following which CCK-8 solution was added and the culture was incubated for 2 h under 5% CO 2 at 37˚C. The absorbance was read at 450 nm on a microplate reader (Thermo Fisher Scientific, Inc.), with the value directly proportional to the number of viable cells in the culture medium.
Flow cytometric analysis. Flow cytometric analysis was performed using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (KeyGen, Nanjing, China) according to the manufacturer's protocol. Primary hippocampal neurons were briefly trypsinized and then washed twice with cold 1X PBS. The cells were pelleted by centrifugation at 425 x g for 5 min at 4˚C and resuspended in 1X binding buffer followed by incubation with staining solution of annexin V-FITC and propidium iodide (PI) for 10 min in the dark at 4˚C. The samples were maintained on ice during the entire procedure and analyzed immediately using flow cytometry. The cells from each sample (10,000 cells) were scanned and analyzed using a FACS Calibur flow cytometer (Becton Dickinson; BD Biosciences, San Diego, CA, USA). Necrosis and apoptosis were determined by PI (FL2) and annexin V-FITC (FL1) fluorescence, respectively. The percentages of apoptotic cells in each sample were estimated.
Semiquantitative RT-PCR. Total RNA from primary hippocampal neurons in each of the different groups was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The reagents for semiquantitative RT-PCR were those supplied with the RevertAid TM First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.). First-strand cDNA was generated from the total RNA (2 µg) by reverse transcription. PCR was performed in a total volume of 25 µl (2 µl cDNA, 0.5 µl of 10 µM each primer, 10 µl PCR master mix and 12 µl sterilized, deionized water). The PCR reaction conditions were as follows: Denaturation at 94˚C for 45 sec, annealing at 59.1˚C (BDNF), 55.6˚C (Bcl-2) or 57.5˚C (GAPDH) for 30 sec, and extension at 72˚C for 30 sec. Primer sequences were as follows: BDNF, forward 5'-AGC CTC CTC TGC TCT TTC TGC TGG A-3' and reverse 5'-CTT TTG TCT ATG CCC CTG CAG CCT T-3'; Bcl-2, forward 5'-GGT GGT GGA GGA ACT CTT CA-3' and reverse 5'-CTC ACT TGT GGC CCA GGT AT-3'; GAPDH, forward 5'-ACA GCA ACA GGG TGG TGG AC-3' and reverse 5'-TTT GAG GGT GCA GCG AAC TT-3'. Following PCR amplification, the products were electrophoresed and separated on a 1.5% agarose gel stained with ethidium bromide. Densitometric analyses of bands for specific genes were performed and normalized to the level of the endogenous control mRNA (GAPDH) using Quantity One v5.0 software (Bio-Rad, Berkeley, CA, USA).
Western blot analysis. Following incubation, the cell proteins were extracted on ice for 60 min in Western and IP lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China), which was added to PMSF (1 mM) prior to use and supplemented with protease inhibitor cocktail. Following centrifugation at 4˚C at 17,254 x g for 10 min, the total lysates were separated on 10% SDS-PAGE gels (30 mg/lane; Solarbio, Beijing, China), and electrophoretically transferred onto polyvinylidene fluoride membranes (0.22 µm; EMD Millipore, Billerica, MA, USA). The membranes were blocked in Tris-buffered saline/0.1% Tween-20/5% non-fat milk for 1 h at room temperature, and were then incubated with primary antibodies against Bcl-2 (1:1,000; cat. no. ab32096; Abcam), BDNF (1:1,000; cat. no. ab108319; Abcam), pCREB (1:1,000; cat. no. ab32096; Abcam) and GAPDH (1:5,000; cat. no. sc-25778; Santa Cruz Biotechnology, Inc.) overnight at 4˚C. The membranes were then rinsed in PBS with 0.1% Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibody (1:5,000; cat. no. sc-25778; Santa Cruz Biotechnology, Inc. Dallas, TX, USA) for 30 min at room temperature. Images of the immunoblots were analyzed using Quantity One V5.0 software (Bio-Rad). The level of each protein was normalized with respect to GAPDH, the domestic loading control.
Statistical analysis. SPSS 19 (IBM SPSS, Armonk, NY, USA) and Origin 7.5 (OriginLab, Northampton, MA, USA) were used for statistical analysis. The data are expressed as the mean ± standard deviation, and one-way analysis of variance was performed to estimate significant differences among groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Hippocampal neuron culture. In the present study, immunocytochemical staining with NeuN was used to identify putative neurons, which revealed a population of neuronal cells with >90% purity. These results showed that the hippocampal neurons had been cultured successfully.
Propofol reduces neuronal viability and induces apoptosis in neuronal cultures from the rat hippocampus. The DIV 8 primary hippocampal neurons in the propofol group were exposed to propofol (100 µM for 3 h) in the absence of dexmedetomidine pretreatment. Neuronal injury was then determined using a CCK-8 assay and flow cytometric analysis. The results of the CCK-8 assay revealed that the neuronal viability in the propofol-treated group was reduced by 57.4%, compared with that in the control group (Fig. 1 ). An increase in the percentage of apoptotic cells was also observed in the propofol-treated cells (31.05±4.33%), compared with the control cells (12.26±2.48%), as shown in Fig. 2A and B.
Dexmedetomidine attenuates propofol-induced apoptosis and increases neuronal viability in neuronal cultures from the rat hippocampus. The DIV 8 primary hippocampal neurons in the propofol + dexmedetomidine groups were pretreated with different concentrations (0.001, 0.01, 0.1, 1, 10 and 100 µM) of dexmedetomidine, prior to propofol exposure (100 µM for 3 h), and subjected to a CCK-8 assay and flow cytometric analysis. Dexmedetomidine significantly increased neuronal viability, by up 110%, compared with propofol exposure without dexmedetomidine pretreatment (P<0.05; Fig. 1 ). No significant differences in cell viability were found among the 10-100 µM dexmedetomidine-pretreated cells and the control cells (P>0.05; Fig. 1 ). In the cells pretreated with 0.001, 0.01, 0.1, 1, 10 and 100 µM dexmedetomidine, the apoptotic rates of the cells were 23 all concentration levels assessed in the present study resulted in fewer apoptotic cells, compared with propofol exposure in the absence of dexmedetomidine pretreatment (31.05±4.33%; P<0.05). No significant difference was observed in apoptotic rates between the 100 µM dexmedetomidine-pretreated cells and the control cells (P>0.05; Fig. 2B ).
Propofol decreases the levels of BDNF, Bcl-2 and p-CREB in hippocampal neurons.
The present study evaluated the effects of propofol exposure on the mRNA expression levels of BDNF and Bcl-2, known to be important in cell survival, using a semiquantitative RT-PCR method. Compared with the control cells, the mRNA levels of Bcl-2 ( Fig. 3A and B) and BDNF ( Fig. 3C and D) in the cells treated with propfol were reduced by 72.4 and 60.3%, respectively (P<0.05). Consistent with the results of the semiquantitative RT-PCR analysis, western blot analysis (Fig. 4A) revealed that the protein levels of BDNF (Fig. 4B ) and Bcl-2 (Fig. 4C ) in the cells treated with propofol were reduced by 63.5 and 64.5%, respectively, compared with control cells (P<0.05). Propofol also significantly decreased the protein level of p-CREB, by 59.0%, compared with the control (P<0.05; Fig. 4D ).
Dexmedetomidine attenuates the propofol-induced reduction in the expression levels of BDNF, Bcl-2 and p-CREB in hippocampal neurons.
The semiquantitative RT-PCR analysis revealed that the treatment of DIV 8 primary hippocampal neurons with dexmedetomidine at concentrations of 0.001,0.01,0.1,1,10 and 100 µM, prior to propofol exposure (100 µM for 3 h), significantly increased the mRNA expression of Bcl-2 by 87.2, 132.0, 139.6, 143.4, 164.2 and 165.3%, respectively, compared with the cells exposed to propofol without dexmedetomidine pretreatment (P<0.05; Fig. 3A  and B) . Similarly, increases of 35.1, 38.8, 58.0, 90.4, 108.1 and 135.1%, respectively, were detected in the mRNA levels of BDNF in the dexmedetomidine-pretreated cells, compared to the propofol-treated cells (P<0.05; Fig. 3C and D) . Consistent with the results of the semiquantitative RT-PCR analysis, dexmedetomidine significantly increased the protein levels of BDNF and Bcl-2, compared with the cells exposed to propofol 05; Fig. 4B ).
Discussion
The present study used neuronal cultures from the rat hippocampus to investigate the neuroprotective effect of dexmedetomindine against propofol-induced neurotoxicity in vitro. The results showed that 100 µM propofol triggered Figure 3 . Dex attenuates Pro-induced reductions in the mRNA expression levels of BDNF and Bcl-2 in immature hippocampal neurons. The cells (8 days in vitro) were exposed to Pro (100 µM, 3 h) in the absence or presence of Dex pretreatment (0.001, 0.01, 0.1, 1, 10 and 100 µM). The mRNA levels of (A and B) BDNF and (C and D) Bcl-2, were determined using semiquantitative reverse transcription-quantitative polymerase chain reaction analysis, in which the densities of bands for BDNF and Bcl-2 were determined and standardized to the mRNA levels of GAPDH. Data are presented as the mean ± standard deviation of at least three independent experiments. * P<0.05 and ** P<0.01, compared with group C; # P<0.05 and ## P<0.01, compared with group Pro. Dex, dexmedetomidine; C, control; Pro, propofol; BDNF; brain-derived neurotrophic factor; Bcl-2, B-cell lymphoma 2.
A B C D immature hippocampal neuron (DIV 8) apoptosis, reduced neuronal viability and caused a reduction in the levels of p-CREB, BDNF and Bcl-2. Pretreatment of the DIV 8 neurons with 0.001-100 µM dexmedetomindine prior to propofol exposure attenuated the propofol-induced neuronal apoptosis and reduction in neuronal viability, and was accompanied by increases in the levels of p-CREB, Bcl-2 and BDNF. These in vitro data indicated that dexmedetomidine prevented propofol-induced neurotoxicity in neuronal cultures from the rat hippocampus, which was associated with upregulation in the expression levels of p-CREB, BDNF and Bcl-2.
Several studies have demonstrated that the administration of anesthetics, including isoflurane, ketamine and propofol, trigger neuronal apoptosis in developing rodent and NHP brains (6, (16) (17) (18) . In the present study DIV 8 hippocampal neurons were used to represent a model of immature and developing neurons. Primary neurons at DIV7-8 are sensitive to anesthetics, and it has been shown that high doses of propofol induce marked neuroapoptosis in the neonatal brain (4, 19) . In aggregated cell cultures, propofol at a high concentration of 10 µg/ml has been reported to produce neurotoxic effects on neurons (20) . In the present study, the concentration of propofol selected (100 µM) was sufficiently high enough to induce neurotoxicity, which was confirmed by preliminary experiments. Therefore, the hippocampal neurons at DIV 8 in the present study were treated with 100 µM propofol in the follow-up experiment. The present study found that exposure of immature neurons to 100 µM propofol for 3 h resulted in a significant reduction in neuronal viability and increase in the percentage of apoptotic cells, as indicated using the CCK-8 assay and flow cytometric analysis. This indicated that propofol exposure induced neuronal injury and apoptosis. These results are in accordance with previous in vitro reports on the neurotoxicity of propofol (3, 21) . In the present study, propofol exposure provoked neuronal damage in vitro and demonstrated that this damage was attenuated by dexmedetomidine.
Dexmedetomidine has been shown to exert neuroprotective effects against neurotoxicity induced by anesthetics, including isoflurane and ketamine, in the developing brain (9, 10, 22, 23) . However, there is no data available on whether dexmedetomidine provides neuroprotective properties against propofol-induced neurotoxicity in the developing brain. The present study assessed the neuroprotective effect 
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of dexmedetomidine on neuronal cultures from the rat hippocampus. Based on the previous studies of Sanders et al (22) and Dahmani et al (24) , the concentration range of dexmedetomidine was extended (0.001-100 µM) in the present study. A marked increase in neuronal viability and reduction in the rate of neuronal apoptosis were observed in the cells pretreated with dexmedetomidine at concentrations between 0.001 and 100 µM. This suggested that dexmedetomidine attenuated the negative effects of propofol on neuronal viability and survival in the rat hippocampal neuronal cultures. Unlike a previous study by Laudenbach et al (25) , which found that dexmedetomidine concentrations of 10 and 100 µM provided less neuroprotection, compared with lower concentrations in vitro, maximal neuroprotection was observed at the highest concentration of dexmedetomidine (100 µM) in the present study, as revealed using an CCK-8 assay and flow cytometric analysis. At this concentration, no significant differences in neuronal viability or apoptosis were found between the dexmedetomidine + propofol group and the control group, which indicated that 100 µM dexmedetomidine caused complete reversal of the neuronal injury induced by propofol in vitro. Other in vivo studies have reported that dexmedetomidine at a high concentration attenuates the neurotoxicity caused by ketamine completely (23), but it is unable to completely attenuate the cortical injury caused by isoflurane (22). This discrepancy may be due to differences in the experimental approach and anesthetics used in these studies. The present study also investigated whether alterations in the levels of p-CREB, Bcl-2 and BDNF are involved in the neuroprotective effects of dexmedetomidine. The mechanisms underlying the neuroprotective effects of dexmedetomidine remain to be fully elucidated. Previous studies have indicated that dexmedetomidine-induced neuroprotection is mediated partially by the activation of α2-adrenergic receptors (9), the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways (26) , the phosphoinositide 3-kinase/Akt pathway (10) , and the extracellular signal-regulated kinase (ERK)1/2 pathways (27) . CREB, a transcription factor family member, can be activated by activation of ERK1/2 and Akt pathways (28) . The activation of CREB was has been suggested to regulate the expression of the genes associated with neuronal survival, synaptic plasticity and memory maintenance (29, 30) . Whether CREB pathways are involved in the neuroprotective effects of dexmedetomidine remain to be fully elucidated. CREB is located upstream of neurotrophins. The phosphorylation of CREB at Ser-133 (p-CREB) regulates the transcription of pro-survival factors, including BDNF and Bcl-2. Increases in the levels of BDNF and p-CREB are observed in the process of neuroprotection following neuronal injury (31, 32) . Bcl-2, as a key apoptosis inhibitory protein, determines the mitochondrial response to apoptotic stimuli, and protects cells from apoptosis (33) . In the present study, semiquantitative RT-PCR and western blot analyses revealed decreases in the expression levels of p-CREB, BDNF and Bcl-2 following propofol administration. Dexmedetomidine treatment prior to propofol exposure significantly attenuated the propofol-induced neuroapoptosis and increased the expression levels of p-CREB, BDNF and Bcl-2 compared with the propofol only group. These findings suggested that propofol-induced neurotoxicity was associated with lower levels of p-CREB, BDNF and Bcl-2, and revealed a link between the upregulation of p-CREB, BDNF and Bcl-2 and the protective effect of dexmedetomindine against propofol-induced neuronal damage caused in developing neurons.
The present study had a number of limitations. Firstly, whether dexmedetomidine itself is directly toxic to immature neurons and whether it inhibits developmental neuroapoptosis, a normal physiologic process in the developing brain, were not investigated. However, several studies have shown that dexmedetomidine itself does not induce neuronal apoptosis in the developing brain of rodents (9, 22) or NHPs (34) . Secondly, due to the size of the subjects, in vivo experiments were not performed immediately following the in vitro experiments . Therefore, careful in vivo experiments are required to confirm the in vitro findings obtained in the present study to determine the correlation between the concentrations and protective efficacy of dexmedetomidine, and to investigate the underlying molecular mechanisms in the developing brain.
In conclusion, the present study demonstrated that dexmedetomidine attenuated propofol-induced neurotoxicity in neuronal cultures from the rat hippocampus, and this was associated with an increase in the levels of p-CREB, BDNF and Bcl-2. The results of the present study contribute to the increasing body of evidence that dexmedetomidine exerts neuroprotective properties.
